RxDoctor Payments Data

David Williams, MD

Nephrology · Norman, OKNPI 1518991264

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Otsuka America Pharmaceutical, Inc. accounts for 64.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $4,416 and has fallen 85.8% since, to $625 in 2025.

$6,352in general payments, 2019–2025

Across 118 payments — averaging $53.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$4K
  • AstraZeneca$702
  • Amgen$373
  • Bayer$247
  • Travere Therapeutics, Inc.$202
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$126
  • plus $619 from 15 others

What the payments were for

  • Consulting fees$3,75359%
  • Food & beverage$2,46339%
  • Education$1362%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,352 in reported general payments places this provider in the 80th percentile of 106 nephrology providers in Oklahoma.

See all nephrology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$220,782
Medicare patients
521
Services billed
1,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol51$63,417
ProcritEpoetin Alfa11$46,095
KerendiaFinerenone22$26,960
Sevelamer Carbonate34$21,304
MyrbetriqMirabegron11$8,947
Torsemide73$2,367
Febuxostat18$2,216
Potassium Chloride40$1,133
Minoxidil23$993
Hydralazine Hcl37$988
Amlodipine Besylate86$843
Metolazone35$719
Calcitriol35$658
Metoprolol Succinate28$608
Carvedilol41$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$702$63,41751 claims
BayerKerendia$247$26,96022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 nephrology providers in Oklahoma.

Other nephrology in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →